Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Jul;28(1):45–52. doi: 10.1111/j.1365-2125.1989.tb03504.x

Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.

P H Dunselman 1, B Edgar 1, A H Scaf 1, C E Kuntze 1, H Wesseling 1
PMCID: PMC1379969  PMID: 2673315

Abstract

1. In a randomized, parallel, double-blind study felodipine was administered to 11 and placebo to 12 patients with congestive heart failure. The kinetics of felodipine were studied after acute intravenous administration and after chronic oral treatment for 8 weeks. The relationship between cardiac output and pharmacokinetics was analyzed. The pharmacokinetic data were compared with data from young healthy individuals and hypertensive patients. 2. After oral therapy, significant correlations were found between cardiac output and AUC and systemic bioavailability (F). Furthermore, cardiac output before therapy was also significantly correlated with absorption characteristics. No relationship could be demonstrated between cardiac output and i.v. pharmacokinetics. A comparison of patients with heart failure and young healthy individuals revealed that the AUC was three times higher in heart failure patient, while Vss and the ratio of the AUC of the pyridine metabolite to that of felodipine were similar. Oral clearance was reduced by 50% and the terminal half-life was concomitantly increased. Pharmacokinetic data for felodipine are similar in patients with heart failure to published data from elderly hypertensive patients. 3. An increase in liver blood flow during chronic oral therapy, induced by felodipine itself, appears to explain an increase in bioavailability and thus to higher plasma drug concentrations. Thus, it is advisable to start felodipine treatment at a low dosage in patients with congestive heart failure.

Full text

PDF
45

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahnoff M., Ervik M., Johansson L. Comparison of high-selectivity gas chromatographic methods, including column switching, for the determination of felodipine in plasma. J Chromatogr. 1987 May 29;394(3):419–427. doi: 10.1016/s0021-9673(01)83809-7. [DOI] [PubMed] [Google Scholar]
  2. Challenor V. F., Waller D. G., Renwick A. G., Gruchy B. S., George C. F. The trans-hepatic extraction of nifedipine. Br J Clin Pharmacol. 1987 Oct;24(4):473–477. doi: 10.1111/j.1365-2125.1987.tb03200.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Edgar B., Collste P., Haglund K., Regårdh C. G. Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. Clin Invest Med. 1987 Sep;10(5):388–394. [PubMed] [Google Scholar]
  4. Edgar B., Regårdh C. G., Johnsson G., Johansson L., Lundborg P., Löfberg I., Rönn O. Felodipine kinetics in healthy men. Clin Pharmacol Ther. 1985 Aug;38(2):205–211. doi: 10.1038/clpt.1985.160. [DOI] [PubMed] [Google Scholar]
  5. Edgar B., Regårdh C. G., Lundborg P., Romare S., Nyberg G., Rönn O. Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm Drug Dispos. 1987 May-Jun;8(3):235–248. doi: 10.1002/bdd.2510080305. [DOI] [PubMed] [Google Scholar]
  6. Feely J. Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects. Br J Clin Pharmacol. 1984 Jan;17(1):83–85. doi: 10.1111/j.1365-2125.1984.tb05003.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hedner T., Samuelsson O., Sjögren E., Elmfeldt D. Treatment of essential hypertension with felodipine in combination with a diuretic. Eur J Clin Pharmacol. 1986;30(2):133–139. doi: 10.1007/BF00614290. [DOI] [PubMed] [Google Scholar]
  8. Kassis E., Amtorp O., Waldorff S., Fritz-Hansen P. Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress. Br Heart J. 1987 Nov;58(5):505–511. doi: 10.1136/hrt.58.5.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kleinbloesem C. H., van Brummelen P., Faber H., Danhof M., Vermeulen N. P., Breimer D. D. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol. 1984 Nov 15;33(22):3721–3724. doi: 10.1016/0006-2952(84)90165-5. [DOI] [PubMed] [Google Scholar]
  10. Leithe M. E., Margorien R. D., Hermiller J. B., Unverferth D. V., Leier C. V. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation. 1984 Jan;69(1):57–64. doi: 10.1161/01.cir.69.1.57. [DOI] [PubMed] [Google Scholar]
  11. Leonetti G., Gradnik R., Terzoli L., Fruscio M., Rupoli L., Cuspidi C., Sampieri L., Zanchetti A. Effects of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients. J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1243–1248. doi: 10.1097/00005344-198611000-00022. [DOI] [PubMed] [Google Scholar]
  12. Ljung B. Vascular selectivity of felodipine. Drugs. 1985;29 (Suppl 2):46–58. doi: 10.2165/00003495-198500292-00011. [DOI] [PubMed] [Google Scholar]
  13. Meredith P. A., Pasanisi F., Elliott H. L., Reid J. L. The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. Br J Clin Pharmacol. 1985 Sep;20(3):235–237. doi: 10.1111/j.1365-2125.1985.tb05066.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Meyer M. C., Guttman D. E. Dynamic dialysis as a method for studying protein binding. I. Factors affecting the kinetics of dialysis through a cellophane membrane. J Pharm Sci. 1970 Jan;59(1):33–38. doi: 10.1002/jps.2600590104. [DOI] [PubMed] [Google Scholar]
  15. Peck C. C., Beal S. L., Sheiner L. B., Nichols A. I. Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm. 1984 Oct;12(5):545–558. doi: 10.1007/BF01060132. [DOI] [PubMed] [Google Scholar]
  16. Pond S. M., Tozer T. N. First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet. 1984 Jan-Feb;9(1):1–25. doi: 10.2165/00003088-198409010-00001. [DOI] [PubMed] [Google Scholar]
  17. Sheiner L. B., Beal S. L. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985 Apr;13(2):185–201. doi: 10.1007/BF01059398. [DOI] [PubMed] [Google Scholar]
  18. Waller D. G., Renwick A. G., Gruchy B. S., George C. F. The first pass metabolism of nifedipine in man. Br J Clin Pharmacol. 1984 Dec;18(6):951–954. doi: 10.1111/j.1365-2125.1984.tb02569.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]
  20. van Harten J., Burggraaf J., Danhof M., van Brummelen P., Breimer D. D. The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration. Br J Clin Pharmacol. 1989 May;27(5):581–586. doi: 10.1111/j.1365-2125.1989.tb03420.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES